Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
B-NHL-M-2021 Protocol for Pediatric B-NHL
NCT05518383Phase 4Recruiting
- Sponsor
- Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology
- Start
- May 2022
- Primary completion
- May 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 4, open-label trial of rituximab in B-cell non-Hodgkin lymphoma, sponsored by Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology. Primary endpoint: Event-Free Survival at 7 years. Started May 2022; status: recruiting.
02
Drugs
rituximab
03
Conditions
B-cell non-Hodgkin lymphoma
Beyond the preview
Go deeper on NCT05518383.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05518383.